Charcot Fund: fundamental research

Validation of age-associated B cells as therapeutic targets in MS

We aim to find targets specific for pro-inflammatory age-associated B cells could lead to a more specific and efficient new therapy for MS.

Aging of the immune system occurs during normal aging but also in a proportion of individuals with MS, and is characterized by elevated frequencies of age-associated B cells in the blood. Our previous research indicated that these age-associated B cells were also present in the cerebrospinal fluid and showed pro-inflammatory functions that could contribute to the disease. Therefore, removing or blocking of these age-associated B cells could be useful in MS therapy. We are currently identifying targets for therapy that are specifically expressed in these age-associated B cells. In this project, we aim to validate the effectiveness of blocking these targets as a therapy for MS. This could eventually lead to a more specific and personalized treatment for MS.

Stay informed

Receive all the information related to research and news from the Charcot Foundation directly in your inbox.

By clicking on “I register”, you agree to our Privacy policy